Signal Explorer
10-K · 10-Q · 8-K · last 6 months · ← back to feed
Dare Bioscience, Inc.
DARE
Other
Equity Plan Board Approval Conditional On Shareholder Vote
Other
Corporate Organization And Standing Representation
New York Jurisdiction Clause
Market Price Definition
Auditor Appointment Ratification
Covenant Compliance Affirmation
Ipo Net Proceeds Disclosure
Amendment Modification Waiver Clause
Corporate Authority Representation
Form S3 Shelf Registration Disclosure
Institutional Investment
No Broker Fees Representation
Registration Rights Piggyback Provision
Use Of Proceeds Disclosure
Warrant Exercise Share Delivery
Fcpa Compliance Representation
Other
Rsu Psu Vesting Schedule Disclosed
Net Loss Reported
Liquidity Position Snapshot Disclosed
Cash Flow Statement Investing Activities
Nasdaq Minimum Bid Price Delisting Notice
Section 409A Compliance Statement
Financing Activities Cash Flow Disclosure
Capital Raising Uncertainty Disclosed
Fair Value Hierarchy Reconciliation Disclosed
Protocol Amended
Sga Expense Comparison Disclosed
Equity Plan Amendment Restriction
Ipo Net Proceeds Disclosure
Core
Secondary Endpoint Mentioned
Clinical Trial Result
Core
Lead Asset Progress
Clinical Trial Result
Indication Expansion
Clinical Hold
Patient Enrollment Velocity
Other
Interim Data Positive
Enrollment Ahead Of Schedule
Personnel Cost Decrease Disclosure
Expanded Access Program Active
Other
Nasdaq Minimum Bid Price Delisting Notice
Other
Say On Pay Vote Result Disclosed
Equity Plan Board Approval Conditional On Shareholder Vote
Ltip Plan Title Citation
Auditor Appointment Ratification
Adjournment Proposal Voting Requirement
Equity Plan Share Reserve Disclosure
Other
Liquidity Position Snapshot Disclosed
Net Loss Reported
Nasdaq Minimum Bid Price Delisting Notice
Sga Expense Comparison Disclosed
Cash Flow Statement Investing Activities
Fair Value Hierarchy Reconciliation Disclosed
Ipo Or Capital Raising Completion
Other Income Expense Disclosure
Ipo Net Proceeds Disclosure
Institutional Investment
Convertible Debt Conversion
Financing Activities Cash Flow Disclosure
Biotech Risk
Accelerated Approval
Core
Clinical Trial Result
Indication Expansion
Other
Ceo Team Pride Statement
Patient Retention High
Liquidity Position Snapshot Disclosed
Administrative Efficiency
Personnel Cost Decrease Disclosure
Interim Data Positive
Core
Clinical Trial Result
Lead Asset Progress
Combination Therapy Mentioned
Indication Expansion
Clinical Hold
Biotech Risk
Clinical Hold Active
Other
Classified Board Director Election